References
- 1. Adelman, D. & Holman, C., (2009). “Misplaced Fears in the Legislative Battle Over Affordable Biotech Drugs”. Idea, Vol.50 No.4, pp.565–591.
- 2. AWA, (2012). “Lifescience Zurich Booklet”, Zurich.
- 3. Bloomberg, (2014). “Bloomberg”. visual data.
- 4. Boschma, R., Heimeriks, G. & Balland, P.-A., (2014). “Scientific knowledge dynamics and relatedness in biotech cities”. Research Policy, Vol.43 No.1, pp.107–114.
- 5. Brada, J.C., Kutan, A.M. & Yigit, T.M., (2006). “The effects of transition and political instability on foreign direct investment inflows.”. The Economics of Transition, Vol.14 No.4, pp.649–680.
- 6. Coan, T.D. & Ron, E., (2001). “Generic Biologics: The Next Frontier”, London.
- 7. Consortium, S.G. et al., (2008). “Protein production and purification”., Vol.5 No.2.
- 8. Debackere, K. & Veugelers, R., (2005). “The role of academic technology transfer organizations in improving industry science links”. Research Policy, Vol.34 No.3, pp.321–342.
- 9. EAER, (2014). “Swiss Biotech Report 2014”,
- 10. Van Epps, H.L., (2006). “Singapore’s multibillion dollar gamble.”. The Journal of experimental medicine, Vol.203 No.5, pp.1139–42.
- 11. Ereky, K., (1919). “Biotechnologie der Fleisch-, Fett-, und Milcherzeugung im landwirtschaftlichen Grossbetriebe: für naturwissenschaftlich gebildete Landwirte verfasst”, Berlin: P. Parey.
- 12. Ernst & Young, (2013). “Beyond borders: global biotechnology report 2013”. Beyond borders, No.27.
- 13. Essendorfer, S., Diaz-Rainey, I. & Falta, M., (2015). “Creative destruction in Wall Street’s technological arms race: Evidence from patent dataNo Title”. Technological Forecasting and Social Change.
- 14. Fári, M.G. & Kralovánszky, U.P., (2006). “The founding father of biotechnology: Károly (Karl) Ereky”. International Journal of Horticultural Science, Vol.12 No.1, pp.9–12.
- 15. Farrell, D., (2005). “Offshoring: Value creation through economic change”. Journal of Management Studies, Vol.42 No.3, pp.675–683.
- 16. Gerstein, M.B. et al., (2007). “What is a gene, post-ENCODE? History and updated definition.”. Genome research, Vol.17 No.6, pp.669–81.
- 17. Glick, J.L., (2008). “Biotechnology business models work: Evidence from the pharmaceutical marketplace”. Journal of Commercial Biotechnology, Vol.14 No.2, pp.106–117.
- 18. Gregersen, N. et al., (2006). “Protein misfolding and human disease.”. Annual review of genomics and human genetics, Vol.7, pp.103–24.
- 19. Grullon, G., Lyandres, E. & Zhdanov, A., (2012). “Real Options, Volatility, and Stock Returns”. Journal of Finance, Vol.67 No.4, pp.1499–1537.
- 20. Hollanders, H. & Es-Sadki, N., (2014). “Innovation Union Scoreboard 2014”, Maastricht.
- 21. Hulse, J.H., (2004). “Biotechnologies: past history, present state and future prospects”. Trends in Food Science & Technology, Vol.15 No.1, pp.3–18.
- 22. IMD, (2013). “International Institute for Management Development”. world competitiveness online.
- 23. JLL, (2012). “NoLife Sciences Outlook Switzerland. 2012”, Zurich.
- 24. Junkunc, M.T., (2007). “Managing radical innovation: The importance of specialized knowledge in the biotech revolution”. Journal of Business Venturing, Vol.22 No.3, pp.388–411.
- 25. Kim, W.C. & Mauborgne, R., (2004). “Blue ocean strategy”. Harvard Business Review, Vol.82 No.10, pp.76–84.
- 26. Kishore, G.M. & Shewmaker, C., (1999). “Biotechnology: Enhancing human nutrition in developing and developed worlds”. Proceedings of the National Academy of Sciences, Vol.96 No.11, pp.5968–5972.
- 27. Kochanova, A., (2012). “The Impact of Bribery on Firm Performance: Evidence from Central and Eastern European Countries”, The Center for Economic Research and Graduate Education - Economic Institute, Prague.
- 28. Kogan, L., Papanikolaou, D. & Stoffman, N., (2015). “Winners and Losers: Creative Destruction and the Stock Market”,
- 29. Kolev, A. & Saget, C., (2005). “Understanding youth labour market disadvantage: Evidence from south-east Europe”. International Labour Review, Vol.144 No.2, pp.161–187.
- 30. Kozlowski, J., Radosevic, S. & Ircha, D., (1999). “History matters: The inherited disciplinary structure of the post-communist science in countries of central and eastern Europe and its restructuring”. Scientometrics, Vol.45 No.1, pp.137–166.
- 31. Lim, L.P.L. & Gregory, M.J., (2004). “Singapore’s biomedical science sector development strategy: Is it sustainable?”. Journal of Commercial Biotechnology, Vol.10 No.4, pp.352–362.
- 32. Meyer, M., (2003). “Academic entrepreneurs or entrepreneurial academics? research-based ventures and public support mechanisms”.
- 33. MLSC, (2014). “Massachusetts Life Sciences Center”.
- 34. Mungiu-pippidi, A., (2014). “The Transformative Power of Europe Revisited”. Journal of Democracy, Vol.25 No.1, pp.20–32.
- 35. NCES, (2014). “National Center for Education Statistics”.
- 36. Nicholson, S., Danzon, P. & McCullough, J., (2002). “Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality”, Cambridge, MA.
- 37. OECD, (2014). “Defining biotechnology”.
- 38. OECD, (2013). “Employment and Labour Markets: Key Tables from OECD”, OECD Productivity Statistics.
- 39. Owen-Smith, J. & Powell, W.W., (2006). “Accounting for Emergence and Novelty in Boston and Bay Area Biotechnology”. In P. Braunerhjelm & M. P. Feldman, eds. Cluster Genesis: Technology-Based Industrial Development. Oxford Scholarship, pp. 1–39.
- 40. Pearson, H., (2006). “Genetics: what is a gene?”. Nature, Vol.441 No.7092, pp.398–401.
- 41. Rader, R.A., (2008). “(Re)defining biopharmaceutical.”. Nature biotechnology, Vol.26 No.7, pp.743–51.
- 42. Radosevic, S. & Auriol, L., (1999). “Patterns of restructuring in research, development and innovation activities in central and eastern European countries: an analysis based on S&T indicators”. Research Policy, Vol.28 No.4, pp.351–376.
- 43. Rossi, M., Tarba, S.Y. & Raviv, A., (2013). “Mergers and acquisitions in the hightech industry: a literature review”. International Journal of Organizational Analysis, Vol.21 No.1, pp.66–82.
- 44. Schafer, S., (2011). “Top 20 Countries in ALL FIELDS”. Essential Science Indicators.
- 45. Schwab, K. & Sala-i-Martín, X., (2014). “The Global Competitiveness Report”,
- 46. Senker, J., Enzing, C. & Reiss, T., (2012). “Biotechnology in Central and Eastern Europe: An overview of performance and policy system”. In Exploring Central and Eastern Europe’s Biotechnology Landscape. pp. 13–35.
- 47. ShanghaiRanking, (2014). “Academic Ranking of World Universities 2013”.
- 48. UNSD, (2011). “Expert Group discusses future work on classifications”, New York.
- 49. Waldmann, T. a, (2003). “Immunotherapy: past, present and future.”. Nature medicine, Vol.9 No.3, pp.269–77.
- 50. Walsh, G., (2014). “Biopharmaceutical benchmarks 2014”. Nature biotechnology, Vol.32 No.7, pp.992–1000.
- 51. WEF, (2014). “Labor market efficiency”. In The Global Competitiveness Report 2013-2014. World Economic Forum, p. 10.
- 52. Wolfe, R.M., (2012). “Business R & D Performed in the United States Cost $ 291 Billion in 2008 and $ 282 Billion in 2009”,
- 53. Wong, P.-K., Ho, Y.-P. & Singh, A., (2009). “Industrial Cluster Development and Innovation in Singapore”. In A. Kuchiki & M. Tsuji, eds. From Agglomeration to Innovation. IDE-JETRO, pp. 50–116.
- 54. WorldBank, (2014)(a). “GDP growth (annual %)”. World Development Indicators.
- 55. WorldBank, (2014)(b). “Research and development expenditure (% of GDP)”. World Development Indicators.
- 56. WorldBank, (2014)(c). “Scientific and technical journal articles”. World Development Indicators.
- 57. Wurm, F.M., (2004). “Production of recombinant protein therapeutics in cultivated mammalian cells.”. Nature biotechnology, Vol.22 No.11, pp.1393–8.
- 58. Yamaner, M., (2012). “Federal Funds for Research and Development: Fiscal Year 2009-11”,
- 59. Zürcher, J., (2005). “Swiss Biotech Report 2005”, Winterthur.